Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""MONTALBAN, X"" wg kryterium: Autor


Tytuł :
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
Autorzy :
Giovannoni G; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK. .
Knappertz V; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Steinerman JR; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Tansy AP; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Li T; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Krieger S; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Uccelli A; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Uitdehaag BMJ; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Montalban X; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Hartung HP; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Pia Sormani M; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Cree BAC; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Lublin F; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Barkhof F; From Barts and The London School of Medicine and Dentistry (G.G.), Blizard Institute, Queen Mary University of London, UK; Teva Pharmaceuticals R&D (V.K.), Teva Pharmaceutical Industries (T.L.), Great Valley, PA; Department of Neurology, Medical Faculty (V.K., H.-P.H.), Heinrich-Heine Universität Düsseldorf, Germany; Teva Pharmaceutical Industries (J.R.S., A.P.T.), Malvern, PA; Corinne Goldsmith Dickinson Center for Multiple Sclerosis (S.K.) and Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health and Center of Excellence for Biomedical Research (A.U.) and Department of Health Sciences (M.P.S.), University of Genoa; Ospedale Policlinico San Martino-IRCCS (A.U.), Genoa, Italy; Department of Neurology (B.M.J.U.), MS Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Division of Neurology (X.M.), University of Toronto/MS Centre St Michael's Hospital, Canada; Neurology-Neuroimmunology Department and Neurorehabilitation Unit (X.M.), Multiple Sclerosis Centre of Catalonia; Department of Neurology (X.M.), Hospital Universitari de la Vall d'Hebron, Barcelona, Spain; Weill Institute for Neurosciences (B.A.C.C.), Department of Neurology, University of California San Francisco; Radiology & Nuclear Medicine (F.L.), VU University Medical Center, Amsterdam, the Netherlands; and UCL Institutes of Neurology and Healthcare Engineering (F.B.), London, UK.
Pokaż więcej
Źródło :
Neurology [Neurology] 2020 Aug 25; Vol. 95 (8), pp. e1027-e1040. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain/*pathology
Multiple Sclerosis, Chronic Progressive/*drug therapy
Quinolones/*therapeutic use
Adult ; Atrophy ; Brain/drug effects ; Disease Progression ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Multiple Sclerosis, Chronic Progressive/pathology ; Spinal Cord/drug effects ; Spinal Cord/pathology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis.
Autorzy :
Clarke MA; From the Vall d'Hebron Research Institute (M.A.C., D.P., M.A., M.T., J.S.-G., C.A., X.M., A.R.), Barcelona, Spain.
Pareto D; From the Vall d'Hebron Research Institute (M.A.C., D.P., M.A., M.T., J.S.-G., C.A., X.M., A.R.), Barcelona, Spain.; Section of Neuroradiology, Department of Radiology (D.P., L.P.-F., C.A., A.R.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pessini-Ferreira L; Section of Neuroradiology, Department of Radiology (D.P., L.P.-F., C.A., A.R.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arrambide G; Department of Neurology-Neuroimmunology (G.A., M.T., J.S.-G., X.M.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Alberich M; From the Vall d'Hebron Research Institute (M.A.C., D.P., M.A., M.T., J.S.-G., C.A., X.M., A.R.), Barcelona, Spain.
Crescenzo F; Department of Neurosciences, Biomedicine and Movement Sciences (F.C.), University of Verona, Verona, Italy.
Cappelle S; Division of Radiology (S.C.), University Hospital Leuven, Leuven, Belgium.
Tintoré M; From the Vall d'Hebron Research Institute (M.A.C., D.P., M.A., M.T., J.S.-G., C.A., X.M., A.R.), Barcelona, Spain.; Department of Neurology-Neuroimmunology (G.A., M.T., J.S.-G., X.M.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sastre-Garriga J; From the Vall d'Hebron Research Institute (M.A.C., D.P., M.A., M.T., J.S.-G., C.A., X.M., A.R.), Barcelona, Spain.; Department of Neurology-Neuroimmunology (G.A., M.T., J.S.-G., X.M.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Auger C; From the Vall d'Hebron Research Institute (M.A.C., D.P., M.A., M.T., J.S.-G., C.A., X.M., A.R.), Barcelona, Spain.; Section of Neuroradiology, Department of Radiology (D.P., L.P.-F., C.A., A.R.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; From the Vall d'Hebron Research Institute (M.A.C., D.P., M.A., M.T., J.S.-G., C.A., X.M., A.R.), Barcelona, Spain.; Department of Neurology-Neuroimmunology (G.A., M.T., J.S.-G., X.M.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; Division of Neurology (X.M.), St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Evangelou N; Division of Clinical Neuroscience (N.E.), University of Nottingham, Nottingham, UK.
Rovira À; From the Vall d'Hebron Research Institute (M.A.C., D.P., M.A., M.T., J.S.-G., C.A., X.M., A.R.), Barcelona, Spain .; Section of Neuroradiology, Department of Radiology (D.P., L.P.-F., C.A., A.R.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
AJNR. American journal of neuroradiology [AJNR Am J Neuroradiol] 2020 Jun; Vol. 41 (6), pp. 1001-1008. Date of Electronic Publication: 2020 May 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain/*diagnostic imaging
Demyelinating Diseases/*diagnostic imaging
Multiple Sclerosis/*diagnostic imaging
Neuroimaging/*methods
Adult ; Aged ; Brain/pathology ; Demyelinating Diseases/pathology ; Female ; Humans ; Image Interpretation, Computer-Assisted ; Magnetic Resonance Imaging/methods ; Male ; Middle Aged ; Multiple Sclerosis/pathology ; Sensitivity and Specificity ; Young Adult
Czasopismo naukowe
Tytuł :
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.
Autorzy :
Sastre-Garriga J; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. .
Pareto D; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Battaglini M; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Rocca MA; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Ciccarelli O; NMR Research Unit, University College London Queen Square Institute of Neurology, London, UK.; National Institute for Health Research Biomedical Research Centre, University College London Hospitals, London, UK.
Enzinger C; Department of Neurology and Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, Graz, Austria.
Wuerfel J; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Sormani MP; Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy.; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.
Barkhof F; National Institute for Health Research Biomedical Research Centre, University College London Hospitals, London, UK.; Amsterdam Neuroscience, MS Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands.; Institutes of Neurology and Healthcare Engineering, University College London, London, UK.
Yousry TA; NMR Research Unit, University College London Queen Square Institute of Neurology, London, UK.; Lysholm Department of Neuroradiology, University College London Hospitals National Hospital for Neurology and Neurosurgery, University College London Institute of Neurology, London, UK.
De Stefano N; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Tintoré M; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Filippi M; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy.
Gasperini C; Multiple Sclerosis Center, Department of Neurosciences, San Camillo-Forlanini Hospital, Rome, Italy.
Kappos L; Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital, University of Basel, Basel, Switzerland.
Río J; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Frederiksen J; Department of Neurology, Rigshospitalet-Glostrup and University of Copenhagen, Glostrup, Denmark.
Palace J; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Vrenken H; Amsterdam Neuroscience, MS Center Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands.
Montalban X; Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.; Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Canada.
Rovira À; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. .
Pokaż więcej
Corporate Authors :
MAGNIMS study group
Źródło :
Nature reviews. Neurology [Nat Rev Neurol] 2020 Mar; Vol. 16 (3), pp. 171-182. Date of Electronic Publication: 2020 Feb 24.
Typ publikacji :
Journal Article; Multicenter Study; Review
MeSH Terms :
Consensus*
Severity of Illness Index*
Brain/*pathology
Magnetic Resonance Imaging/*standards
Multiple Sclerosis/*diagnostic imaging
Practice Guidelines as Topic/*standards
Spinal Cord/*diagnostic imaging
Atrophy/diagnostic imaging ; Atrophy/pathology ; Brain/diagnostic imaging ; Humans ; Magnetic Resonance Imaging/methods ; Multiple Sclerosis/pathology ; Prognosis ; Randomized Controlled Trials as Topic/standards ; Spinal Cord/pathology
Czasopismo naukowe
Tytuł :
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.
Autorzy :
Sinnecker T; Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital, University of Basel, Basel, Switzerland.; Medical Image Analysis Center, Basel, Switzerland.; Neurocure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; qbig, Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Clarke MA; School of Psychology, University of Nottingham, Nottingham, United Kingdom.; Clinical Neurology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
Meier D; Medical Image Analysis Center, Basel, Switzerland.; qbig, Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
Enzinger C; Division of Neuroradiology, Vascular and Interventional Radiology, Departments of Neurology and Radiology, Medical University of Graz, Graz, Austria.
Calabrese M; Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
De Stefano N; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Pitiot A; Laboratory of Image and Data Analysis, Ilixa Ltd, London, United Kingdom.
Giorgio A; Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Schoonheim MM; Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Paul F; Neurocure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health and Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Pawlak MA; Department of Neurology and Cerebrovascular Disorders, Poznan University of Medical Sciences, Poznan, Poland.
Schmidt R; Department of Neurology, Medical University of Graz, Graz, Austria.
Kappos L; Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital, University of Basel, Basel, Switzerland.
Montalban X; Section of Neuroradiology, Department of Radiology (IDI), VHIR, Barcelona, Spain.; Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Rovira À; Section of Neuroradiology, Department of Radiology (IDI), VHIR, Barcelona, Spain.
Evangelou N; Division of Clinical Neuroscience, University of Nottingham, Nottingham, United Kingdom.
Wuerfel J; Medical Image Analysis Center, Basel, Switzerland.; Neurocure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; qbig, Department of Biomedical Engineering, University of Basel, Basel, Switzerland.; Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health and Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Pokaż więcej
Corporate Authors :
MAGNIMS Study Group
Źródło :
JAMA neurology [JAMA Neurol] 2019 Dec 01; Vol. 76 (12), pp. 1446-1456.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Brain/*diagnostic imaging
Cerebral Veins/*diagnostic imaging
Multiple Sclerosis, Relapsing-Remitting/*diagnostic imaging
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Case-Control Studies ; Cluster Headache/diagnostic imaging ; Cross-Sectional Studies ; Demyelinating Diseases/diagnostic imaging ; Female ; Humans ; Lupus Vasculitis, Central Nervous System/diagnostic imaging ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Migraine Disorders/diagnostic imaging ; Multiple Sclerosis/diagnostic imaging ; Neuromyelitis Optica/diagnostic imaging ; Sensitivity and Specificity ; Young Adult
Czasopismo naukowe
Tytuł :
Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome.
Autorzy :
Pareto D; Neuroradiology Section, Department of Radiology, Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain. .
Sastre-Garriga J; Department of Neuroimmunology (Cemcat), Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University, Barcelona, Spain.
Alberich M; Neuroradiology Section, Department of Radiology, Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Auger C; Neuroradiology Section, Department of Radiology, Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Tintoré M; Department of Neuroimmunology (Cemcat), Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University, Barcelona, Spain.
Montalban X; Department of Neuroimmunology (Cemcat), Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University, Barcelona, Spain.
Rovira À; Neuroradiology Section, Department of Radiology, Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Pokaż więcej
Źródło :
Neuroradiology [Neuroradiology] 2019 Jun; Vol. 61 (6), pp. 667-674. Date of Electronic Publication: 2019 Mar 05.
Typ publikacji :
Journal Article
MeSH Terms :
Brain/*pathology
Image Interpretation, Computer-Assisted/*methods
Magnetic Resonance Imaging/*methods
Multiple Sclerosis/*pathology
Acute Disease ; Adult ; Atrophy/pathology ; Female ; Humans ; Imaging, Three-Dimensional ; Longitudinal Studies ; Male ; Organ Size
Czasopismo naukowe
Tytuł :
The Central Vein Sign in Radiologically Isolated Syndrome.
Autorzy :
Suthiphosuwan S; From the Division of Neuroradiology (S.S., A.B.).; Division of Neurology (S.S., M.G., X.M., J.O.), Department of Medicine.
Sati P; Translational Neuroradiology Section (P.S., D.S.R.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
Guenette M; Division of Neurology (S.S., M.G., X.M., J.O.), Department of Medicine.
Montalban X; Division of Neurology (S.S., M.G., X.M., J.O.), Department of Medicine.
Reich DS; Translational Neuroradiology Section (P.S., D.S.R.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.; Department of Neurology (D.S.R., J.O.), Johns Hopkins University, Baltimore, Maryland.
Bharatha A; From the Division of Neuroradiology (S.S., A.B.).; Division of Neurosurgery (A.B.), Department of Surgery, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Oh J; Division of Neurology (S.S., M.G., X.M., J.O.), Department of Medicine .; Department of Neurology (D.S.R., J.O.), Johns Hopkins University, Baltimore, Maryland.
Pokaż więcej
Źródło :
AJNR. American journal of neuroradiology [AJNR Am J Neuroradiol] 2019 May; Vol. 40 (5), pp. 776-783. Date of Electronic Publication: 2019 Apr 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain/*pathology
Demyelinating Diseases/*pathology
Spinal Cord/*pathology
Adult ; Female ; Humans ; Magnetic Resonance Imaging/methods ; Male ; Middle Aged ; Multiple Sclerosis/pathology ; Risk Factors
Czasopismo naukowe
Tytuł :
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.
Autorzy :
Rotstein D; Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Montalban X; Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. .; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain. .
Pokaż więcej
Źródło :
Nature reviews. Neurology [Nat Rev Neurol] 2019 May; Vol. 15 (5), pp. 287-300.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Evidence-Based Medicine*
Precision Medicine*
Brain/*diagnostic imaging
Immunologic Factors/*therapeutic use
Multiple Sclerosis/*drug therapy
Biomarkers ; Disease Progression ; Humans ; Magnetic Resonance Imaging ; Multiple Sclerosis/diagnostic imaging ; Prognosis
Czasopismo naukowe
Tytuł :
Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis.
Autorzy :
Pareto D; Section of Neuroradiology, Department of Radiology, University Hospital Vall d'Hebron, Barcelona, Spain.
Sastre-Garriga J; Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain.
Alonso J; Section of Neuroradiology, Department of Radiology, University Hospital Vall d'Hebron, Barcelona, Spain.
Galán I; Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain.
Arévalo MJ; Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain.
Renom M; Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain.
Montalban X; Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain.
Rovira À; Section of Neuroradiology, Department of Radiology, University Hospital Vall d'Hebron, Barcelona, Spain.
Pokaż więcej
Źródło :
Journal of neuroimaging : official journal of the American Society of Neuroimaging [J Neuroimaging] 2018 May; Vol. 28 (3), pp. 313-319. Date of Electronic Publication: 2018 Feb 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Neurological Rehabilitation*
Brain/*diagnostic imaging
Magnetic Resonance Imaging/*methods
Multiple Sclerosis/*diagnostic imaging
Adult ; Brain Mapping/methods ; Female ; Humans ; Male ; Middle Aged ; Multiple Sclerosis/rehabilitation ; Reproducibility of Results ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.
Autorzy :
Vidal-Jordana A; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sastre-Garriga J; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pareto D; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tur C; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain/National Hospital for Neurology and Neurosurgery, Queen Square MS Centre, UCL Institute of Neurology, London, UK.
Arrambide G; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Otero-Romero S; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Huerga E; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Mitjana R; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Auger C; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tintoré M; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rovira A; Section of Neuroradiology and Magnetic Resonance Unit, Department of Radiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2018 May; Vol. 24 (6), pp. 721-727. Date of Electronic Publication: 2017 Apr 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain/*pathology
Demyelinating Diseases/*pathology
Adult ; Atrophy ; Cohort Studies ; Demyelinating Diseases/complications ; Disability Evaluation ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Prospective Studies
Czasopismo naukowe
Tytuł :
Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus.
Autorzy :
Carrillo-Salinas FJ; Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Madrid, Spain.; Red Española de Esclerosis Múltiple (REEM), Spain.
Mestre L; Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Madrid, Spain.; Red Española de Esclerosis Múltiple (REEM), Spain.
Mecha M; Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Madrid, Spain.; Red Española de Esclerosis Múltiple (REEM), Spain.
Feliú A; Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Madrid, Spain.; Red Española de Esclerosis Múltiple (REEM), Spain.
Del Campo R; Servicio de Microbiología, Hospital Universitario Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, and Red Española de Investigación en Patología Infecciosa (REIPI), Sevilla, Spain.
Villarrubia N; Immunology Department, Hospital Universitario Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Espejo C; Red Española de Esclerosis Múltiple (REEM), Spain.; Servei de Neurología-Neuroimmunología, Centre d'Esclerosi Múltiple de Catalunya, Valld'Hebron Institut de Recerca, Hospital Universitari Valld'Hebron, 08035 Barcelona, Spain.; Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain.
Montalbán X; Red Española de Esclerosis Múltiple (REEM), Spain.; Servei de Neurología-Neuroimmunología, Centre d'Esclerosi Múltiple de Catalunya, Valld'Hebron Institut de Recerca, Hospital Universitari Valld'Hebron, 08035 Barcelona, Spain.; Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain.
Álvarez-Cermeño JC; Red Española de Esclerosis Múltiple (REEM), Spain.; Multiple Sclerosis Unit, Neurology Department, University of Alcalá, Madrid, Spain.
Villar LM; Red Española de Esclerosis Múltiple (REEM), Spain.; Immunology Department, Hospital Universitario Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Guaza C; Grupo de Neuroinmunología, Departamento de Neurobiología Funcional y de Sistemas, Instituto Cajal, CSIC, Madrid, Spain.; Red Española de Esclerosis Múltiple (REEM), Spain.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2017 Mar 14; Vol. 7, pp. 44377. Date of Electronic Publication: 2017 Mar 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain/*immunology
Dysbiosis/*immunology
Gastrointestinal Microbiome/*immunology
Multiple Sclerosis/*immunology
Animals ; Brain/microbiology ; Brain/physiopathology ; Brain/virology ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Dysbiosis/microbiology ; Dysbiosis/pathology ; Dysbiosis/virology ; Humans ; Lymph Nodes/immunology ; Lymph Nodes/microbiology ; Lymph Nodes/virology ; Lymphocyte Activation/immunology ; Mice ; Multiple Sclerosis/microbiology ; Multiple Sclerosis/pathology ; Multiple Sclerosis/virology ; Neuroimmunomodulation ; Spinal Cord/immunology ; Spinal Cord/microbiology ; Spinal Cord/pathology ; Spinal Cord/virology ; Theilovirus/immunology ; Theilovirus/pathogenicity
Czasopismo naukowe
Tytuł :
Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics.
Autorzy :
Vidal-Jordana A; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sastre-Garriga J; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pérez-Miralles F; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pareto D; Magnetic Resonance Unit, Radiology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rio J; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Auger C; Magnetic Resonance Unit, Radiology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tintoré M; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rovira A; Magnetic Resonance Unit, Radiology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Journal of neuroimaging : official journal of the American Society of Neuroimaging [J Neuroimaging] 2016 Sep; Vol. 26 (5), pp. 532-8. Date of Electronic Publication: 2016 Mar 02.
Typ publikacji :
Journal Article
MeSH Terms :
Magnetic Resonance Imaging*
Brain/*pathology
Immunologic Factors/*pharmacology
Interferon-beta/*pharmacology
Multiple Sclerosis/*pathology
Adult ; Atrophy/pathology ; Brain/drug effects ; Brain/physiopathology ; Disease Progression ; Female ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Inflammation/diagnostic imaging ; Inflammation/physiopathology ; Interferon-beta/adverse effects ; Interferon-beta/therapeutic use ; Male ; Multiple Sclerosis/drug therapy ; Organ Size ; Prospective Studies
Czasopismo naukowe
Tytuł :
Power estimation for non-standardized multisite studies.
Autorzy :
Keshavan A; Department of Neurology, University of California, San Francisco, CA, USA; UC Berkeley-UCSF Graduate Program in Bioengineering, San Francisco, CA, USA. Electronic address: .
Paul F; NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany; Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité University Medicine Berlin, Berlin, Germany. Electronic address: .
Beyer MK; Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. Electronic address: .
Zhu AH; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: .
Papinutto N; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: .
Shinohara RT; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. Electronic address: .
Stern W; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: .
Amann M; Department of Neurology, Basel University Hospital, University of Basel, Basel, Switzerland. Electronic address: .
Bakshi R; Brigham and Women's Hospital, MA, United States. Electronic address: .
Bischof A; Department of Neurology, University of California, San Francisco, CA, USA; Department of Neurology, Basel University Hospital, University of Basel, Basel, Switzerland; Clinical Immunology, University Hospital Basel,University of Basel, Basel, Switzerland. Electronic address: .
Carriero A; Department of Translational Medicine, Department of Radiology, UPO University, Via Solaroli 17, 28100 Novara, Italy. Electronic address: .
Comabella M; Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: .
Crane JC; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA. Electronic address: .
D'Alfonso S; Department of Health Sciences, UPO University, Novara, Italy. Electronic address: .
Demaerel P; Department of Radiology, University Hospitals Leuven, Leuven, Belgium. Electronic address: .
Dubois B; KU Leuven-University of Leuven, Department of Neurosciences, Leuven, Belgium. Electronic address: .
Filippi M; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: .
Fleischer V; Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Centre of the Johannes Gutenberg University Mainz, Germany. Electronic address: .
Fontaine B; Hôpital Pitié-Salpêtrière, ICM, UPMC 06 UM 75, INSERM U 1127, CNRS UMR 7225, IHU-A-ICM, AP-HP: Pôle des maladies du système nerveux, 47 boulevard de l'Hôpital, 75013 Paris, France. Electronic address: .
Gaetano L; Department of Neurology, Basel University Hospital, University of Basel, Basel, Switzerland; Medical Image Analysis Center (MIAC AG), Basel, Switzerland. Electronic address: .
Goris A; KU Leuven-University of Leuven, Department of Neurosciences, Leuven, Belgium. Electronic address: .
Graetz C; Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Centre of the Johannes Gutenberg University Mainz, Germany. Electronic address: .
Gröger A; Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Centre of the Johannes Gutenberg University Mainz, Germany. Electronic address: .
Groppa S; Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Centre of the Johannes Gutenberg University Mainz, Germany. Electronic address: .
Hafler DA; Departments of Neurology and Immunobiology, Yale School of Medicine, CT, USA. Electronic address: .
Harbo HF; Department of Neurology, Oslo University Hospital and University of Oslo, Oslo, Norway. Electronic address: .
Hemmer B; Dept. Neurology of the Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Munich Cluster of Systems Neurology (SyNery), Germany. Electronic address: .
Jordan K; Department of Neurology, University of California, San Francisco, CA, USA; UC Berkeley-UCSF Graduate Program in Bioengineering, San Francisco, CA, USA. Electronic address: .
Kappos L; Department of Neurology, Basel University Hospital, University of Basel, Basel, Switzerland. Electronic address: .
Kirkish G; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA. Electronic address: .
Llufriu S; Center for Neuroimmunology, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain. Electronic address: .
Magon S; Department of Neurology, Basel University Hospital, University of Basel, Basel, Switzerland. Electronic address: .
Martinelli-Boneschi F; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: .
McCauley JL; John P. Hussman Institute for Human Genomics and the Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, USA. Electronic address: .
Montalban X; Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: xavier.montalban@cem-cat.org.
Mühlau M; Dept. Neurology of the Klinikum rechts der Isar, Technische Universität München, Munich, Germany; TUM-Neuroimaging Center, Technische Universität München, Munich, Germany. Electronic address: .
Pelletier D; Departments of Neurology and Immunobiology, Yale School of Medicine, CT, USA. Electronic address: .
Pattany PM; Department of Radiology, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: .
Pericak-Vance M; John P. Hussman Institute for Human Genomics and the Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, USA. Electronic address: .
Cournu-Rebeix I; Hôpital Pitié-Salpêtrière, ICM, UPMC 06 UM 75, INSERM U 1127, CNRS UMR 7225, IHU-A-ICM, AP-HP: Pôle des maladies du système nerveux, 47 boulevard de l'Hôpital, 75013 Paris, France. Electronic address: .
Rocca MA; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: .
Rovira A; Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: .
Schlaeger R; Department of Neurology, University of California, San Francisco, CA, USA; Department of Neurology, Basel University Hospital, University of Basel, Basel, Switzerland; Clinical Immunology, University Hospital Basel,University of Basel, Basel, Switzerland. Electronic address: .
Saiz A; Center for Neuroimmunology, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain. Electronic address: .
Sprenger T; Department of Neurology, Basel University Hospital, University of Basel, Basel, Switzerland; DKD Helios Klinik Wiesbaden, Wiesbaden, Germany. Electronic address: .
Stecco A; Section of Neuroradiology, Department of Radiology, Maggiore Hospital, Corso Mazzini 18, 28100, Novara, Italy. Electronic address: .
Uitdehaag BMJ; MS Center Amsterdam, VU University Medical Center Amsterdam, The Netherlands. Electronic address: .
Villoslada P; Center for Neuroimmunology, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain. Electronic address: .
Wattjes MP; MS Center Amsterdam, VU University Medical Center Amsterdam, The Netherlands. Electronic address: .
Weiner H; Brigham and Women's Hospital, MA, United States. Electronic address: .
Wuerfel J; NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité University Medicine Berlin, Berlin, Germany; Medical Image Analysis Center, Basel, Switzerland. Electronic address: .
Zimmer C; Dept. Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. Electronic address: .
Zipp F; Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Centre of the Johannes Gutenberg University Mainz, Germany. Electronic address: .
Hauser SL; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: .
Oksenberg JR; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: .
Henry RG; Department of Neurology, University of California, San Francisco, CA, USA; UC Berkeley-UCSF Graduate Program in Bioengineering, San Francisco, CA, USA; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA. Electronic address: .
Pokaż więcej
Corporate Authors :
International Multiple Sclerosis Genetics Consortium. Electronic address: ; International Multiple Sclerosis Genetics Consortium, USA, EU, AU.
Źródło :
NeuroImage [Neuroimage] 2016 Jul 01; Vol. 134, pp. 281-294. Date of Electronic Publication: 2016 Apr 01.
Typ publikacji :
Comparative Study; Evaluation Study; Journal Article; Multicenter Study
MeSH Terms :
Artifacts*
Models, Statistical*
Brain/*anatomy & histology
Image Interpretation, Computer-Assisted/*instrumentation
Image Interpretation, Computer-Assisted/*methods
Magnetic Resonance Imaging/*instrumentation
Magnetic Resonance Imaging/*methods
Algorithms ; Computer Simulation ; Equipment Design ; Equipment Failure Analysis ; Europe ; Humans ; Image Enhancement/instrumentation ; Image Enhancement/methods ; Reproducibility of Results ; Sensitivity and Specificity ; United States
Czasopismo naukowe
Tytuł :
Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load.
Autorzy :
Pareto D; Unitat de Ressonància Magnètica (Servei de Radiologia, IDI), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain. .
Sastre-Garriga J; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Aymerich FX; Unitat de Ressonància Magnètica (Servei de Radiologia, IDI), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.; Departament D'Enginyeria de Sistemes, Automàtica i Informàtica Industrial (ESAII), Universitat Politècnica de Catalunya (UPC), Barcelona, Spain.
Auger C; Unitat de Ressonància Magnètica (Servei de Radiologia, IDI), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Tintoré M; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rovira A; Unitat de Ressonància Magnètica (Servei de Radiologia, IDI), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Pokaż więcej
Źródło :
Neuroradiology [Neuroradiology] 2016 May; Vol. 58 (5), pp. 467-74. Date of Electronic Publication: 2016 Feb 04.
Typ publikacji :
Evaluation Study; Journal Article
MeSH Terms :
Brain/*diagnostic imaging
Brain/*pathology
Diffusion Tensor Imaging/*methods
Image Interpretation, Computer-Assisted/*methods
Imaging, Three-Dimensional/*methods
Multiple Sclerosis/*diagnostic imaging
Multiple Sclerosis/*pathology
Adult ; Female ; Humans ; Image Enhancement/methods ; Male ; Organ Size ; Reproducibility of Results ; Sensitivity and Specificity ; White Matter/diagnostic imaging ; White Matter/pathology
Czasopismo naukowe
Tytuł :
Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.
Autorzy :
Vidal-Jordana A; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Sastre-Garriga J; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain. .
Rovira A; Magnetic Resonance Unit, Radiology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Pokaż więcej
Źródło :
Journal of neurology [J Neurol] 2015 Dec; Vol. 262 (12), pp. 2617-26. Date of Electronic Publication: 2015 Jun 05.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Brain/*drug effects
Brain/*pathology
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Multiple Sclerosis, Relapsing-Remitting/*pathology
Humans
Czasopismo naukowe
Tytuł :
Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling.
Autorzy :
Valverde S; Dept. of Computer Architecture and Technology, University of Girona, Spain.
Oliver A; Dept. of Computer Architecture and Technology, University of Girona, Spain.
Roura E; Dept. of Computer Architecture and Technology, University of Girona, Spain.
Pareto D; Magnetic Resonance Unit, Dept. of Radiology, Vall d'Hebron University Hospital, Spain Architecture and Technology, University of Girona, Spain.
Vilanova JC; Girona Magnetic Resonance Center, Spain.
Ramió-Torrentà L; Multiple Sclerosis and Neuro-immunology Unit, Dr. Josep Trueta University Hospital, Spain.
Sastre-Garriga J; Neurology Unit, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Spain.
Montalban X; Neurology Unit, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Spain.
Rovira À; Magnetic Resonance Unit, Dept. of Radiology, Vall d'Hebron University Hospital, Spain Architecture and Technology, University of Girona, Spain.
Lladó X; Dept. of Computer Architecture and Technology, University of Girona, Spain.
Pokaż więcej
Źródło :
NeuroImage. Clinical [Neuroimage Clin] 2015 Oct 28; Vol. 9, pp. 640-7. Date of Electronic Publication: 2015 Oct 28 (Print Publication: 2015).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Pattern Recognition, Automated*
Brain/*pathology
Magnetic Resonance Imaging/*methods
Multiple Sclerosis/*pathology
Gray Matter/pathology ; Humans ; Image Processing, Computer-Assisted/methods ; Reproducibility of Results ; White Matter/pathology
Czasopismo naukowe
Tytuł :
Defining high, medium and low impact prognostic factors for developing multiple sclerosis.
Autorzy :
Tintore M; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain .
Rovira À; 2 Unitat de RM. Servei de Radiologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Río J; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Otero-Romero S; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arrambide G; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tur C; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Comabella M; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Nos C; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Arévalo MJ; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Negrotto L; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Galán I; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Vidal-Jordana A; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Castilló J; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Palavra F; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Simon E; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Mitjana R; 2 Unitat de RM. Servei de Radiologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Auger C; 2 Unitat de RM. Servei de Radiologia, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sastre-Garriga J; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; 1 Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Brain : a journal of neurology [Brain] 2015 Jul; Vol. 138 (Pt 7), pp. 1863-74. Date of Electronic Publication: 2015 Apr 21.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain/*pathology
Multiple Sclerosis/*cerebrospinal fluid
Multiple Sclerosis/*pathology
Oligoclonal Bands/*cerebrospinal fluid
Adult ; Cohort Studies ; Demyelinating Diseases/pathology ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Risk Factors
Czasopismo naukowe
Tytuł :
Brain atrophy in natalizumab-treated patients: A 3-year follow-up.
Autorzy :
Sastre-Garriga J; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain .
Tur C; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pareto D; Unitat de Ressonància Magnètica (Servei de Radiologia), Hospital universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Vidal-Jordana A; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Auger C; Unitat de Ressonància Magnètica (Servei de Radiologia), Hospital universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Río J; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Huerga E; Unitat de Ressonància Magnètica (Servei de Radiologia), Hospital universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Tintoré M; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rovira A; Unitat de Ressonància Magnètica (Servei de Radiologia), Hospital universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Montalban X; Servei de Neurologia / Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2015 May; Vol. 21 (6), pp. 749-56. Date of Electronic Publication: 2014 Nov 12.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Disease Progression*
Brain/*pathology
Immunologic Factors/*pharmacology
Multiple Sclerosis/*drug therapy
Multiple Sclerosis/*pathology
Natalizumab/*pharmacology
Adult ; Atrophy/pathology ; Brain/drug effects ; Follow-Up Studies ; Humans ; Inflammation/drug therapy ; Inflammation/pathology ; Magnetic Resonance Imaging/methods ; Middle Aged ; Severity of Illness Index ; Time Factors
Czasopismo naukowe
Tytuł :
Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes.
Autorzy :
Mitjana R; MR Unit (IDI), Department of Radiology, and Department of Neurology-Neuroimmunology, CEM-CAT, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Tintoré M; MR Unit (IDI), Department of Radiology, and Department of Neurology-Neuroimmunology, CEM-CAT, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Rocca MA; Neuroimaging Research Unit, Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Auger C; MR Unit (IDI), Department of Radiology, and Department of Neurology-Neuroimmunology, CEM-CAT, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Barkhof F; Department Neurology, VU University Medical Centre, Amsterdam, The Netherlands.
Filippi M; Neuroimaging Research Unit, Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Polman C; Department Neurology, VU University Medical Centre, Amsterdam, The Netherlands.
Fazekas F; Department of Neurology, Medical University of Graz, Austria.
Huerga E; MR Unit (IDI), Department of Radiology, and Department of Neurology-Neuroimmunology, CEM-CAT, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Montalban X; MR Unit (IDI), Department of Radiology, and Department of Neurology-Neuroimmunology, CEM-CAT, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Rovira A; MR Unit (IDI), Department of Radiology, and Department of Neurology-Neuroimmunology, CEM-CAT, Hospital Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain .
Pokaż więcej
Źródło :
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2014 Oct; Vol. 20 (11), pp. 1471-7. Date of Electronic Publication: 2014 Feb 27.
Typ publikacji :
Journal Article
MeSH Terms :
Magnetic Resonance Imaging*/methods
Brain/*pathology
Demyelinating Diseases/*diagnosis
Adult ; Aged ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Risk ; Time Factors
Czasopismo naukowe
Tytuł :
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Autorzy :
Filippi M; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Ospedale San Raffaele, Milan, Italy Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Ospedale San Raffaele, Milan, Italy.
Rocca MA; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Ospedale San Raffaele, Milan, Italy Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Ospedale San Raffaele, Milan, Italy.
Pagani E; Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Ospedale San Raffaele, Milan, Italy.
De Stefano N; Quantitative Neuroimaging Laboratory, Department of Neurology, Neurosurgery & Behavioral Sciences, University of Siena, Siena, Italy.
Jeffery D; Cornerstone Health Care, North Carolina, USA.
Kappos L; Clinical Neuroimmunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Montalban X; Clinical Neuroimmunology, Vall d'Hebron University Hospital and University of Autonoma de Barcelona, Barcelona, Spain.
Boyko AN; Department of Neurology and Neurosurgery, Russian State Medical University and Moscow MS Center, Moscow, Russia.
Comi G; Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Ospedale San Raffaele, Milan, Italy.
Pokaż więcej
Corporate Authors :
ALLEGRO Study Group
Źródło :
Journal of neurology, neurosurgery, and psychiatry [J Neurol Neurosurg Psychiatry] 2014 Aug; Vol. 85 (8), pp. 851-8. Date of Electronic Publication: 2013 Sep 12.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Brain/*pathology
Multiple Sclerosis/*drug therapy
Multiple Sclerosis/*pathology
Quinolones/*therapeutic use
Adolescent ; Adult ; Aspartic Acid/analogs & derivatives ; Aspartic Acid/blood ; Creatinine/blood ; Disability Evaluation ; Endpoint Determination ; Female ; Humans ; Image Processing, Computer-Assisted ; Magnetic Resonance Imaging ; Magnetic Resonance Spectroscopy ; Male ; Middle Aged ; Quinolones/adverse effects ; Thalamus/pathology ; Treatment Outcome ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies